AbbVie has been working to advance standards of care in gastroenterology for more than 10 years. Our expertise and dedication coupled with our drive for innovation creates a brighter future for patients.
Leaving no patient behind
As we learn more about pathophysiology and optimal disease management
we can set more ambitious goals for tackling IBD in ways that extend
beyond symptoms. For example, tools like our IBD Disk and the Lémann
score help us monitor more IBD patients to identify those with a poor
prognosis. Unlocking effective treatment strategies is vital to
helping modify the course of the disease.
Addressing unmet needs
We currently have over 30 ongoing or planned trials in IBD. By
learning, adapting and innovating, AbbVie aspires to make IBD
patients’ long-term goals possible.
Partnerships with purpose
We work with partners to tackle global challenges in IBD and shape
the future of disease management. Together, we aim to enhance quality
of care by educating on Treat to Target (T2T), demonstrating its
clinical and economic impact, and making non-invasive monitoring
standard for most patients.